TB-500: Research Overview

The short version

TB-500 is the commercial name for a short, seven-amino-acid synthetic fragment (Ac-LKKTETQ) of a larger natural protein called thymosin beta-4. That larger protein is the body's main actin-binding regulator — it helps cells move, migrate, and rebuild structure after injury. Here is the catch worth understanding up front: most of the encouraging research uses the full-length protein, not the small fragment that is actually sold as "TB-500." Whether the short fragment reproduces the full protein's effects has not been established in controlled human trials.

TB-500 is not an approved medicine, has no completed controlled human trial behind it, and is prohibited in competitive sport by the World Anti-Doping Agency. This page reports what studies found — mostly in cells, rodents, and (for the full-length protein) one human Phase 1 safety trial — and recommends no dose and no use for any person.

What it is

TB-500 is a synthetic, N-terminally acetylated heptapeptide, Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH, corresponding to residues 17–23 of the 43-amino-acid endogenous protein thymosin beta-4 (gene TMSB4X). That LKKTETQ motif is the conserved actin-binding region shared across the beta-thymosin family. In commerce and in the analytical and anti-doping literature, "TB-500" specifically denotes this ~889-Da heptapeptide — but the great majority of published efficacy research uses the full-length ~4,963-Da recombinant or synthetic protein instead, a distinction the corpus behind this page flags on every finding that used the full-length form.

How it works

Full-length thymosin beta-4 is the major intracellular actin-sequestering protein in cells: it binds monomeric (globular) actin one-to-one, capping both ends of the monomer to hold a buffered pool of unpolymerized actin and regulate cytoskeletal dynamics, cell migration, and motility ^[10]. In injury models, the protein — and the LKKTETQ region specifically — is associated with faster cell migration, angiogenesis, anti-inflammatory and anti-apoptotic signaling, reduced scar (myofibroblast) formation, and recruitment of progenitor cells ^[8]. A structural study using X-ray crystallography confirmed the 1:1 actin-sequestration mechanism at 2 Å resolution, establishing the biochemical basis for the actin-buffering role ^[10]. In mice, the protein also formed a complex with PINCH and integrin-linked kinase (ILK), activating the survival kinase Akt and improving cardiomyocyte survival and heart function after coronary-artery ligation ^[11]. Whether the isolated seven-amino-acid fragment reproduces these effects at research-use doses is not established.

What the research shows

State of the evidence. A 2026 Sports Medicine narrative review of approved and unapproved peptide therapies for musculoskeletal injuries — including TB-500/thymosin beta-4 alongside BPC-157 — concludes that many unapproved peptides show favorable tissue-repair outcomes in animal models, but that rigorous human safety data are scarce, with potential for serious harm, and that these compounds largely operate outside regulatory oversight ^[6].

Stroke recovery (rat, full-length protein). In male Wistar rats with induced stroke, intraperitoneal thymosin beta-4 at 2 and 12 mg/kg (starting 24 hours post-stroke, then every three days for four more doses) significantly improved neurological function from day 14 through day 56; 18 mg/kg gave no significant benefit, and a modeled optimal dose of roughly 3.75 mg/kg was proposed — a reminder that more is not automatically better ^[7].

Mechanism review. A widely cited review consolidates the mechanism: actin binding, promotion of cell mobilization and migration and stem-cell activity, reduced myofibroblast (scar) formation, release by platelets and macrophages after injury to limit apoptosis and inflammation, and pro-angiogenic activity — the rationale behind clinical trials in dermal wounds, corneal injury, and heart and CNS repair ^[8].

Human Phase 1 safety (full-length protein). In a randomized, placebo-controlled Phase 1 study, synthetic full-length thymosin beta-4 given intravenously to 40 healthy volunteers (four cohorts of ten) — a single dose then daily for 14 days at 42, 140, 420, or 1,260 mg — was well tolerated with only infrequent mild-to-moderate adverse events, no dose-limiting toxicities, and dose-proportional pharmacokinetics ^[9]. This trial used the full-length protein, not the TB-500 fragment.

Structural basis. X-ray crystallography of a thymosin-beta4/actin complex at 2 Å resolution established the 1:1 actin-sequestration mechanism, capping both ends of the monomer to prevent polymerization ^[10].

Cardiac repair (mouse). Thymosin beta-4 formed a functional complex with PINCH and integrin-linked kinase, activating Akt; after coronary-artery ligation it enhanced early cardiomyocyte survival and improved cardiac function ^[11].

Wound healing (rat). Topical or intraperitoneal thymosin beta-4 increased re-epithelialization of full-thickness wounds by 42% at four days and up to 61% at seven days versus saline, increased wound contraction, and raised collagen deposition and angiogenesis; as little as 10 pg stimulated keratinocyte migration two- to three-fold ^[12].

Reported effects, cautions & safety

The following are anecdotal, not clinical evidence — drawn from peptide-user forums, athletic and biohacker community blogs, and research-supplier review pages, never a controlled trial, and never with a dose attached.

Reported benefits (anecdotal): the dominant reason people in research communities reach for TB-500 is faster-feeling recovery from tendon, ligament, and muscle injuries, with widely varying self-reported timelines. Others describe less joint pain and stiffness with better range of motion, improved overall flexibility, a vaguer sense of reduced inflammation or calmed soreness, better wound and skin healing, and — rarely — more hair growth over several weeks (often alongside other interventions).

Reported adverse effects (anecdotal): the most common complaint by far is a small, mild injection-site reaction. Many users report temporary tiredness or lethargy for a day or two, especially early on. Less commonly reported: a brief head rush or headache, a short flu-like feeling, nausea (more with larger self-selected amounts), a heightened awareness of an existing injury, and occasional short-lived low mood.

Cited cautions: there are no completed controlled human trials of the TB-500 fragment itself for any use — the human safety data that exist are for the full-length protein ^[6][9]. Thymosin beta-4 is overexpressed in several cancers and implicated in metastasis and tumor angiogenesis, a theoretical concern for the fragment given the shared pro-migratory, pro-angiogenic mechanism. TB-500 is prohibited by WADA under its peptide and growth-factor categories, and anti-doping labs have developed detection methods for it and its breakdown products ^[6]. It is important to note that the fragment sold commercially is not the same molecule as most of the encouraging efficacy literature ^[8]. Research-grade material is not made to medicine-grade standards, and identity and purity are not guaranteed between suppliers.

Where it fits in recovery & tissue-repair research

As the lead compound in this hub, TB-500 anchors the load-tolerance and return-to-play frame most directly — its underlying mechanism is cell migration and structural remodeling, the literal process of tissue rebuilding after strain ^[8][10]. Reading it next to BPC-157, which leans on new blood-vessel formation, and KLOW, which folds both into an untested four-peptide blend, is the clearest way to see how the three compounds' research bases actually differ. See the comparison page for the full picture.